Cargando…

Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients

This study aimed to investigate whether uric acid to creatinine (UA/Cr) ratio is associated with higher risk of metabolic syndrome (MetS) and its components. 332 adult Saudi type 2 diabetes mellitus (T2DM) patients were divided into UA/Cr tertiles. Risk for full MetS was significantly highest in ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Daghri, Nasser M., Al-Attas, Omar S., Wani, Kaiser, Sabico, Shaun, Alokail, Majed S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608718/
https://www.ncbi.nlm.nih.gov/pubmed/28935934
http://dx.doi.org/10.1038/s41598-017-12085-0
_version_ 1783265478690471936
author Al-Daghri, Nasser M.
Al-Attas, Omar S.
Wani, Kaiser
Sabico, Shaun
Alokail, Majed S.
author_facet Al-Daghri, Nasser M.
Al-Attas, Omar S.
Wani, Kaiser
Sabico, Shaun
Alokail, Majed S.
author_sort Al-Daghri, Nasser M.
collection PubMed
description This study aimed to investigate whether uric acid to creatinine (UA/Cr) ratio is associated with higher risk of metabolic syndrome (MetS) and its components. 332 adult Saudi type 2 diabetes mellitus (T2DM) patients were divided into UA/Cr tertiles. Risk for full MetS was significantly highest in individuals that constitutes the uppermost serum UA/Cr tertile [Odds ratio (OR): 1.80, 95% confidence interval (CI): 1.0–3.3; p < 0.001) after adjustment for age, gender and BMI. Similarly, risk for individual components of MetS like central obesity, hypertriglyceridemia, low HDL-cholesterol and hypertension was significantly highest in this tertile with OR’s of 2.61 (1.2–5.6), 1.42 (0.7–2.3), 1.45 (0.7–2.8) and 1.16 (0.6–2.2) respectively (all p-values < 0.001) after adjustment for age, gender, BMI and other components of MetS. Furthermore, serum UA/Cr levels increased with increasing number of MetS components (mean values of 4.44, 4.49, 4.64, 4.89 and 4.91 respectively for 1,2,3,4 and 5 MetS components, p-values < 0.001 after adjusting for age, gender and BMI). Our data suggest that serum UA/Cr in T2DM patients is strongly associated with full MetS as well as its individual components. These findings are of considerable clinical importance as serum UA/Cr may be used as a marker in the pathogenesis of MetS.
format Online
Article
Text
id pubmed-5608718
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-56087182017-10-04 Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients Al-Daghri, Nasser M. Al-Attas, Omar S. Wani, Kaiser Sabico, Shaun Alokail, Majed S. Sci Rep Article This study aimed to investigate whether uric acid to creatinine (UA/Cr) ratio is associated with higher risk of metabolic syndrome (MetS) and its components. 332 adult Saudi type 2 diabetes mellitus (T2DM) patients were divided into UA/Cr tertiles. Risk for full MetS was significantly highest in individuals that constitutes the uppermost serum UA/Cr tertile [Odds ratio (OR): 1.80, 95% confidence interval (CI): 1.0–3.3; p < 0.001) after adjustment for age, gender and BMI. Similarly, risk for individual components of MetS like central obesity, hypertriglyceridemia, low HDL-cholesterol and hypertension was significantly highest in this tertile with OR’s of 2.61 (1.2–5.6), 1.42 (0.7–2.3), 1.45 (0.7–2.8) and 1.16 (0.6–2.2) respectively (all p-values < 0.001) after adjustment for age, gender, BMI and other components of MetS. Furthermore, serum UA/Cr levels increased with increasing number of MetS components (mean values of 4.44, 4.49, 4.64, 4.89 and 4.91 respectively for 1,2,3,4 and 5 MetS components, p-values < 0.001 after adjusting for age, gender and BMI). Our data suggest that serum UA/Cr in T2DM patients is strongly associated with full MetS as well as its individual components. These findings are of considerable clinical importance as serum UA/Cr may be used as a marker in the pathogenesis of MetS. Nature Publishing Group UK 2017-09-21 /pmc/articles/PMC5608718/ /pubmed/28935934 http://dx.doi.org/10.1038/s41598-017-12085-0 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Al-Daghri, Nasser M.
Al-Attas, Omar S.
Wani, Kaiser
Sabico, Shaun
Alokail, Majed S.
Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients
title Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients
title_full Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients
title_fullStr Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients
title_full_unstemmed Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients
title_short Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients
title_sort serum uric acid to creatinine ratio and risk of metabolic syndrome in saudi type 2 diabetic patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608718/
https://www.ncbi.nlm.nih.gov/pubmed/28935934
http://dx.doi.org/10.1038/s41598-017-12085-0
work_keys_str_mv AT aldaghrinasserm serumuricacidtocreatinineratioandriskofmetabolicsyndromeinsauditype2diabeticpatients
AT alattasomars serumuricacidtocreatinineratioandriskofmetabolicsyndromeinsauditype2diabeticpatients
AT wanikaiser serumuricacidtocreatinineratioandriskofmetabolicsyndromeinsauditype2diabeticpatients
AT sabicoshaun serumuricacidtocreatinineratioandriskofmetabolicsyndromeinsauditype2diabeticpatients
AT alokailmajeds serumuricacidtocreatinineratioandriskofmetabolicsyndromeinsauditype2diabeticpatients